20 Percent Boost in Agilent’s Life Science Sales Drives 7 Percent Q2 Profit Spike | GenomeWeb
NEW YORK (GenomeWeb News) - Agilent Technologies said late yesterday that fiscal second-quarter revenues increased 6 percent as R&D spending increased 1 percent and profit climbed 7 percent.     
 
Revenue for the company's Bio-Analytical Measurement segment increased 15 percent to $428 million from $372 million year over year and Life Sciences revenue was up 20 percent to $194 million, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.